BioSpace News Archive

BioForest

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 22, 2022

CTI BioPharma Corp. announced the grant of equity awards to two new employees as equity inducement awards outside of the Company’s Amended and Restated 2017 Equity Incentive Plan and material to the employees’ acceptance of employment with the company.

September 21, 2022
·
2 min read
FDA

FDA Approves Lilly’s Retevmo® (selpercatinib), the First and Only RET Inhibitor for Adults with Advanced or Metastatic Solid Tumors with a RET Gene Fusion, Regardless of Type

Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) has granted approval to Retevmo® (selpercatinib, 40 mg & 80 mg capsules).

September 21, 2022
·
19 min read
ADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022)

ADC Therapeutics SA (NYSE: ADCT) today announced that ZYNLONTA® (loncastuximab tesirine-lpyl) and camidanlumab tesirine (Cami) abstracts have been accepted for presentation at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022).

September 21, 2022
·
6 min read
Drug Development

RVAC Medicines Initiates First-in-Human Clinical Trials for mRNA COVID-19 Vaccine Candidates

RVAC Medicines Pte. Ltd., a messenger RNA (mRNA) technology platform company incubated by CBC Group in 2021, announced today that a participant has been dosed in a Phase 1, first-in-human study evaluating the company’s mRNA-based COVID-19 vaccine candidate, RVM-V001.

September 21, 2022
·
3 min read
BioForest

CTI BioPharma Announces Presentation of New Anemia Benefit Data from Pacritinib Program at the Society of Hematologic Oncology (SOHO) Tenth Annual Meeting

CTI BioPharma Corp. (NASDAQ: CTIC) today announced two poster presentations from the Company’s pacritinib program at the Society of Hematologic Oncology (SOHO) Tenth Annual Meeting, to be held in Houston, Texas and virtually September 28 – October 1, 2022.

September 21, 2022
·
13 min read
Pixium Vision to host open house event for investors on October 13th 2022 from 5 pm

Pixium Vision SA, a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces it will host an open house event for investors on Thursday, October 13th, 2022.

September 21, 2022
·
3 min read
Basilea announces closing of CHF 75 million senior secured loan agreement with Athyrium

Basilea Pharmaceutica Ltd announced the closing of the previously announced CHF 75 million senior secured loan agreement with funds managed by Athyrium Capital Management, LP.

September 21, 2022
·
2 min read
argenx to Highlight Key Programs from Neuromuscular Franchise at Upcoming Medical Meetings

argenx SE announced the presentation of new data from its neuromuscular franchise at the American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting and the Myasthenia Gravis Foundation of America Scientific Session, both being held in Nashville, TN.

September 21, 2022
·
13 min read
Drug Development

Poxel Announces Positive Histology Results from Phase 2 NASH Trial (DESTINY-1) for PXL065, a Novel, Proprietary Deuterium-Stabilized R-stereoisomer of Pioglitazone

POXEL SA announced positive histology results for DESTINY-1, the dose-ranging Phase 2 trial of PXL065 for the treatment of NASH.

September 21, 2022
·
11 min read
Business

Poxel Reports Financial Results for First Half 2022 and Provides a Corporate Update

POXEL SA announced its financial results for the period ended June 30, 2022 and provided a corporate update.

September 21, 2022
·
14 min read